Format

Send to

Choose Destination
Pathologe. 2015 Feb;36(1):92-7. doi: 10.1007/s00292-014-2069-x.

[Chances and risks of blood-based molecular pathological analysis of circulating tumor cells (CTC) and cell-free DNA (cfDNA) in personalized cancer therapy: positional paper from the study group on liquid biopsy of the working group for molecular pathology in the German Society of Pathology (DGP)].

[Article in German]

Author information

1
Institut für Pathologie, Uniklinik RWTH Aachen, Aachen, Deutschland, edahl@ukaachen.de.
PMID:
25533324
DOI:
10.1007/s00292-014-2069-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center